Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.

Subjects

Subjects :

Humans
Drug Approval
Glucagon-Like Peptide-1 Receptor agonists
Glucagon-Like Peptides therapeutic use
Glucagon-Like Peptides adverse effects
Glucagon-Like Peptides administration & dosage
Cardiovascular Diseases etiology
Cardiovascular Diseases mortality
Cardiovascular Diseases prevention & control
Injections, Subcutaneous
Randomized Controlled Trials as Topic
Diabetes Mellitus, Type 2 drug therapy
Diabetes Mellitus, Type 2 complications
Diabetic Nephropathies drug therapy
Diabetic Nephropathies etiology
Diabetic Nephropathies mortality
Diabetic Nephropathies prevention & control
Hypoglycemic Agents administration & dosage
Hypoglycemic Agents adverse effects
Hypoglycemic Agents therapeutic use
Glucagon-Like Peptide-1 Receptor Agonists administration & dosage
Glucagon-Like Peptide-1 Receptor Agonists adverse effects
Glucagon-Like Peptide-1 Receptor Agonists therapeutic use
Renal Insufficiency, Chronic drug therapy
Renal Insufficiency, Chronic etiology
Renal Insufficiency, Chronic mortality
Renal Insufficiency, Chronic prevention & control
Diabetic Cardiomyopathies etiology
Diabetic Cardiomyopathies mortality
Diabetic Cardiomyopathies prevention & control

Details

Language :

English

ISSN :

1533-4406

Volume :

391

Issue :

2

Database :

MEDLINE

Journal :

The New England journal of medicine

Publication Type :

Editorial & Opinion

Accession number :

38986062

Full Text :

https://doi.org/10.1056/NEJMe2406408